Quality of life and drug compliance: their interrelationship in rheumatic patients

Hromádková, Lenka; Soukup, T.; Vlcek, Jirí

doi:10.1111/jep.12399

Cited by 23 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study demonstrated that using GC has better adherence because most patients with adherence to medication were diagnosed with SLE and RA; in other words, GC was their key drug to relieve symptoms. 28 Different from previous studies, 29 , 30 higher education may contribute to poorer adherence. Maybe the patients with higher education in the cohort were more worried about rheumatic medication-related questions, such as side effects.…”

Section: Discussionmentioning

confidence: 67%

Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram

Wang¹,

Zhang²,

Liu

et al. 2018

PPA

View full text Add to dashboard Cite

PurposeThe aim of this study was to develop and internally validate a medication nonadherence risk nomogram in a Chinese population of patients with inflammatory rheumatic diseases.Patients and methodsWe developed a prediction model based on a training dataset of 244 IRD patients, and data were collected from March 2016 to May 2016. Adherence was evaluated using 19-item Compliance Questionnaire Rheumatology. The least absolute shrinkage and selection operator regression model was used to optimize feature selection for the medication nonadherence risk model. Multivariable logistic regression analysis was applied to build a predicting model incorporating the feature selected in the least absolute shrinkage and selection operator regression model. Discrimination, calibration, and clinical usefulness of the predicting model were assessed using the C-index, calibration plot, and decision curve analysis. Internal validation was assessed using the bootstrapping validation.ResultsPredictors contained in the prediction nomogram included use of glucocorticoid (GC), use of nonsteroidal anti-inflammatory drugs, number of medicine-related questions, education level, and the distance to hospital. The model displayed good discrimination with a C-index of 0.857 (95% confidence interval: 0.807–0.907) and good calibration. High C-index value of 0.847 could still be reached in the interval validation. Decision curve analysis showed that the nonadherence nomogram was clinically useful when intervention was decided at the nonadherence possibility threshold of 14%.ConclusionThis novel nonadherence nomogram incorporating the use of GC, the use of nonsteroidal anti-inflammatory drugs, the number of medicine-related questions, education level, and distance to hospital could be conveniently used to facilitate the individual medication nonadherence risk prediction in IRD patients.

show abstract

Section: Discussionmentioning

confidence: 67%

Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram

Wang¹,

Zhang²,

Liu

et al. 2018

PPA

View full text Add to dashboard Cite

show abstract

“… 36 , 37 Another study recruited patients through the British Society for Rheumatology Biologics Register for RA – a UK-wide prospective observational cohort study established in 2001 for the purpose of monitoring the long-term safety of biologic therapy. 38 In regard to study design, four had a cross-sectional design, 27 , 28 , 31 , 32 five were retrospective cohort studies, 24 – 26 , 34 , 35 and six were prospective studies. 29 , 30 , 33 , 36 – 38 …”

Section: Resultsmentioning

confidence: 99%

Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review

Anghel

Farcaş

Oprean

2018

PPA

View full text Add to dashboard Cite

BackgroundSeveral drugs are available for the treatment of autoimmune rheumatic diseases; however, their effectiveness may be negatively influenced by inappropriate adherence. Low adherence and persistence rates have a significant impact on patient quality of life and are associated with health-related expenses.PurposeTo provide an up-to-date narrative review on treatment adherence and persistence rates, and discuss the factors that influence them, in patients with autoimmune rheumatic diseases.Materials and methodsWe searched the PubMed database for studies among patients with a diagnosis of rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), or psoriatic arthritis (PsA), published from January 2015 to February 2017. Only studies with a well-defined measurement of adherence/persistence and those that carried out an evaluation of the influencing factors were included.ResultsFifteen relevant studies that evaluated adherence and/or persistence were included. Adherence rates varied between 9.3% and 94%, and persistence rates between 23% and 80%. Most of the studies used one method to evaluate adherence or persistence (different questionnaire scores, proportion of days covered, and mean treatment duration). A high concordance was found between the adherence measurements of the Medication Event Monitoring System and Visual Analog Scale. Factors of economic, demographic, and clinical nature were only moderately linked to treatment adherence or persistence. However, patient-related factors – such as positive and increased beliefs in medication necessity, strong views of the chronic nature of the diseases, and increased knowledge of the disease – were related to better treatment adherence.ConclusionOwing to the heterogeneity of the study results, we consider that the use of more than one method to assess adherence/persistence should yield more comprehensive and accurate data about patient adherence behavior. Patient-related factors should be included and analyzed more often in adherence studies as the former may be modified to improve patient adherence.

show abstract

“…Hromadkova et al 26 assessed the relationship between drug compliance and HRQoL in patients with different rheumatic disorders, including SpA. A significantly negative correlation between compliance and HRQoL PCS was found in SpA patients, suggesting that patients with worse HRQoL might be more compliant with treatment.…”

Section: Resultsmentioning

confidence: 99%

“…For long-term persistence, Favalli et al 43 reported cumulative 8-year retention of 57.2% for axSpA and 51.9% for PsA. Finally, related to compliance, Hromadkove et al 26 reported that only 38.3% of patients with AS were compliant with BA treatment, as indicated by Compliance Questionnaire Rheumatology score 80).…”

Section: Resultsmentioning

confidence: 99%

Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature

Torre-Alonso

Queiró

Comellas³

et al. 2018

PPA

View full text Add to dashboard Cite

ObjectiveThis review aims to summarize the current literature on patient-reported outcomes (PROs) in spondyloarthritis (SpA).Patients and methodsWe performed a systematic literature review to identify studies (original articles and narrative and systematic reviews) regarding PROs (health-related quality of life [HRQoL], satisfaction, preferences, adherence/compliance, and persistence) in SpA patients published in the European Union through December 2016. International databases (Medline/PubMed, Cochrane Library, ISI Web of Knowledge, Scopus) were searched using keywords in English. The methodological quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine criteria.ResultsA total of 26 publications met the inclusion criteria. Generally, studies indicated that SpA has a negative impact on patients’ HRQoL. In patients with ankylosing spondylitis, physical domains were more affected than emotional ones, whereas for psoriatic arthritis, both physical and psychological factors were strongly affected by the disease. Data indicated that biological agents (BAs) greatly contributed to improvement in HRQoL in both ankylosing spondylitis and psoriatic arthritis patients. Findings on compliance with BAs were heterogeneous. However, persistence rates exceeded 50% irrespective of the BA administered. Results on preferences indicated that most SpA patients prefer being involved in decisions regarding their treatment and that besides efficacy and safety, frequency and route of administration may influence patients’ preferences for BAs.ConclusionImplementing management programs for SpA patients focuses on the physical, emotional, and social consequences of the disease, in addition to assessing and including patient preferences in the treatment decision-making process, could be crucial to improve patients’ HRQoL and ensure their satisfaction and compliance with treatment.

show abstract

Quality of life and drug compliance: their interrelationship in rheumatic patients

Abstract: Doctors caring for rheumatic patients should focus their efforts on strengthening drug compliance in patients with higher QoL where it seems that lower compliance is more likely.

Cited by 23 publications

References 38 publications

Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram

Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram

Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review

Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature

Contact Info

Product

Resources

About